TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 2956140
Drug: Rado-Salil ointment
Normalized name: SALIX
DrugBank: Willow bark (DB14691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rado-Salil ointment
Study: 27296091
Drug: Aspirin and
Normalized name: Aspirin and Caffeine Tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin and omega-3 fatty acid supplements
Study: 22639959
Drug: Tipifarnib plus
Normalized name: Tipifarnib
DrugBank: Tipifarnib (DB04960)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tipifarnib plus low dose cytarabine (LDAC)
Study: 22639959
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose cytarabine (LDAC)
Study: 8369232
Drug: Chlorpromazine (CPZ)
Normalized name: Chlorpromazine
DrugBank: Chlorpromazine (DB00477)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chlorpromazine (CPZ) 900 mg to 1800 mg per day, stepwise increase over 12 months
Study: 8369232
Drug: Orphenadrine 300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Orphenadrine 300 mg per day
Study: 27612310
Drug: Group intervention
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group intervention (1-hour sessions, 3-5 subjects, twice a week for 12 weeks)
Study: 27612310
Drug: Personal intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Personal intervention (20-minute sessions, one staff member per participant, twice a week for 12 weeks)
Study: 19176895
Drug: Donepezil (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Donepezil (5 mg/day for 6 weeks, then 10 mg/day for 42 weeks)
Study: 17377162
Drug: Evaluation and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Evaluation and treatment options for intermittent claudication, including potential revascularization.
Study: 15592331
Drug: Ciprofloxacin 500
Normalized name: ciprofloxacin 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ciprofloxacin 500 mg twice daily for 3 days
Study: 11380714
Drug: Amethocaine gel
DrugBank: Tetracaine (DB09085)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amethocaine gel (topical application for 30 minutes)
Study: 11380714
Drug: Placebo gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo gel (topical application for 30 minutes)
Study: 8516087
Drug: Sustained‐release theophylline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sustained‐release theophylline administered twice daily
Study: 3521784
Drug: Control (identical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (identical clinical care, no adjuvant chemotherapy)
Study: 10678268
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg urapidil
Study: 24725169
Drug: 0.2 mg
Normalized name: niacin 0.2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.2 mg tamsulosin
Study: 20604720
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg naftopidil
Study: 20604720
Drug: Control therapy
Normalized name: Benzoyl Peroxide;Salicylic Acid;Vitamin E 8%; 2%; 5% Topical application Kit [INOVA 8/2 ACNE CONTROL THERAPY]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control therapy (240 mg flopropione and 1350 mg extract of Quercus salicina Blume/Quercus stenophylla Makino)
Study: 31109906
Drug: Antihypertensive drugs
Normalized name: ANTIHYPERTENSIVES
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antihypertensive drugs prescribed in 157 (87%) participants, median of 1 (IQR 1-2) antihypertensive medication.
Study: 31109906
Drug: Increasing number
Normalized name: Derma Numb
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Increasing number of antihypertensives.
Study: 26308286
Drug: Intravitreal triamcinolone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravitreal triamcinolone (TA) injection
Study: 19141433
Drug: Personalized SMS
Normalized name: Samarium Sm-153
DrugBank: Samarium Sm-153 (DB12905)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Personalized SMS and MMS messages sent 2-5 times daily, printed materials, and brief monthly phone calls from a health counselor.
Study: 19141433
Drug: Monthly printed
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Monthly printed materials about weight control.
Study: 12871894
Drug: tibolone 1.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: tibolone 1.25 mg
Study: 12871894
Drug: estradiol 2
Normalized name: estradiol 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: estradiol 2 mg plus norethisterone acetate 1 mg (E2 + NETA)
Study: 10870872
Drug: Zaleplon 5
Normalized name: zaleplon 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zaleplon 5 mg
Study: 6230950
Drug: Atracurium 0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atracurium 0.2 mg/kg for muscle relaxation
Study: 29083530
Drug: 200 μg/mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 μg/mL amphotericin B nasal irrigation
Study: 15675987
Drug: Continuous physostigmine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous physostigmine infusion combined with morphine-based PCA
Study: 12166337
Drug: 0.3 mg
Normalized name: biotin 0.3 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.3 mg ramosetron intravenously
Study: 10381905
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg aspirin daily for 3 months
Study: 10381905
Drug: 81 mg
Normalized name: aspirin 81 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 81 mg aspirin daily for 3 months
Study: 10381905
Drug: 325 mg
Normalized name: lysine 325 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 325 mg aspirin daily for 3 months
Study: 1844773
Drug: Cefuroxime (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefuroxime (250 mg td) for 7 days
Study: 1844773
Drug: Trimethoprim sulfamethoxazole
Normalized name: sulfamethoxazole / trimethoprim
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trimethoprim sulfamethoxazole (160/800 mg td) for 7 days
Study: 6557966
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg Fenoterol orally before 0.4 mg PGE2 gel
Study: 6557966
Drug: 0.4 mg
Normalized name: biotin 0.4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.4 mg PGE2 gel
Study: 6557966
Drug: 0.8 mg
Normalized name: biotin 0.8 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.8 mg PGE2 gel
Study: 26762497
Drug: 2-octyl cyanoacrylate
Normalized name: 2-octyl cyanoacrylate
DrugBank: 2-octyl cyanoacrylate (DB12040)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2-octyl cyanoacrylate with Opsite (G+O)
Study: 26762497
Drug: 2-octyl cyanoacrylate
Normalized name: 2-octyl cyanoacrylate
DrugBank: 2-octyl cyanoacrylate (DB12040)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2-octyl cyanoacrylate with Tegaderm (G+T)
Study: 21415284
Drug: Eslicarbazepine acetate
Normalized name: Eslicarbazepine Acetate
DrugBank: Eslicarbazepine (DB14575)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Eslicarbazepine acetate 2400 mg
Study: 21415284
Drug: Moxifloxacin 400
Normalized name: moxifloxacin 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moxifloxacin 400 mg (single dose)
Study: 15379365
Drug: EE/DRSP (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: EE/DRSP (30 microg ethinyl estradiol and 3 mg drospirenone)
Study: 15379365
Drug: EE/NGM (35
Approvals — FDA: no, EMA: no, PMDA: no
Description: EE/NGM (35 microg ethinyl estradiol and 0.180, 0.215, 0.250 mg norgestimate)
Study: 11307411
Drug: Laser-assisted therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Laser-assisted therapy (diode laser light, 1-watt output, maximum of 20 seconds)
Study: 8398517
Drug: Amethocaine patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amethocaine patch (30-min application)
Study: 8398517
Drug: Amethocaine patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amethocaine patch (60-min application)
Study: 8398517
Drug: Amethocaine gel
DrugBank: Tetracaine (DB09085)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amethocaine gel preparation
Study: 28728744
Drug: Beta Blocker
Normalized name: Beta blocker
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beta Blocker (BB) use at ≥50% target dose
Study: 25789519
Drug: Estrogen therapy
Normalized name: estrogens
Approvals — FDA: no, EMA: no, PMDA: no
Description: Estrogen therapy (2.0 mg of 17β‐estradiol)
Study: 25789519
Drug: Estrogen‐progestin therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Estrogen‐progestin therapy (2.0 mg of 17 β‐estradiol + 1.0 mg of norethisterone acetate)
Study: 23743559
Drug: Cost analysis
Normalized name: Chemicals and reagents for analysis
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cost analysis for 16 weeks treatment
Study: 23743559
Drug: Cost analysis
Normalized name: Chemicals and reagents for analysis
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cost analysis for 24 weeks treatment
Study: 19451304
Drug: KBPA-101 at
Normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: KBPA-101 at 0.1 mg/kg
Study: 19451304
Drug: KBPA-101 at
Normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: KBPA-101 at 0.4 mg/kg
Study: 19451304
Drug: KBPA-101 at
Normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: KBPA-101 at 1.2 mg/kg
Study: 19451304
Drug: KBPA-101 at
Normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: KBPA-101 at 4.0 mg/kg
Study: 16549451
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg of labeled zinc (67Zn) with 50 mg AA (LoZn group)
Study: 16549451
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg of labeled zinc (67Zn) with 50 mg AA (HiZn group)
Study: 16549451
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg zinc with no AA (control)
Study: 15286543
Drug: Once-daily dosing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once-daily dosing (ODD) of tobramycin (7 mg/kg)
Study: 15286543
Drug: Multiple daily
Normalized name: Multivitamin Oral Tablet [MULTIPLE DAILY W/BETA]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple daily dosing (MDD) of tobramycin
Study: 9331215
Drug: Latanoprost 15
Normalized name: Latanoprost
DrugBank: Latanoprost (DB00654)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Latanoprost 15 microg/ml twice daily
Study: 9331215
Drug: Latanoprost 50
Normalized name: Latanoprost 50 microgram/mL eye drops
Approvals — FDA: no, EMA: no, PMDA: no
Description: Latanoprost 50 microg/ml once daily
Study: 8226140
Drug: Hyperfractionated radiation
Normalized name: allantoin
DrugBank: Allantoin (DB11100)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hyperfractionated radiation therapy to doses of 60.0 Gy, 64.8 Gy, 69.6 Gy, 74.4 Gy, or 79.2 Gy, 1.2 Gy twice daily, 5 days per week.
Study: 8226140
Drug: Hyperfractionated radiation
Normalized name: allantoin
DrugBank: Allantoin (DB11100)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hyperfractionated radiation therapy with deviations in treatment time.
Study: 2418902
Drug: Permixon (160
Approvals — FDA: no, EMA: no, PMDA: no
Description: Permixon (160 mg bd)
Study: 29596150
Drug: Intranasal Oxytocin
Normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intranasal Oxytocin (24 international units)
Study: 25497998
Drug: EPG 10
Normalized name: dyphylline / ephedrine hydrochloride / guaifenesin / phenobarbital Oral Solution [Lufyllin-EPG]
Approvals — FDA: no, EMA: no, PMDA: no
Description: EPG 10 g/day
Study: 25497998
Drug: EPG 25
Normalized name: dyphylline / ephedrine hydrochloride / guaifenesin / phenobarbital Oral Solution [Lufyllin-EPG]
Approvals — FDA: no, EMA: no, PMDA: no
Description: EPG 25 g/day
Study: 25497998
Drug: EPG 40
Normalized name: dyphylline / ephedrine hydrochloride / guaifenesin / phenobarbital Oral Solution [Lufyllin-EPG]
Approvals — FDA: no, EMA: no, PMDA: no
Description: EPG 40 g/day
Study: 22190001
Drug: Testosterone therapy
Normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Testosterone therapy (gel)
Study: 20157843
Drug: Triple therapy
Normalized name: MigreLief Triple Therapy with Puracol Caplet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple therapy (TT) - warfarin, ASA, and clopidogrel
Study: 20157843
Drug: Dual therapy
Normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dual therapy (DT) - ASA and clopidogrel
Study: 19114376
Drug: Full dose
Normalized name: BayRHo-D Full Dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Full dose (1 mg/kg) MTW
Study: 19114376
Drug: Half dose
Normalized name: propranolol hydrochloride Extended Release Oral Capsule [Half-Betadur CR]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Half dose (0.5 mg/kg) MTW
Study: 15825548
Drug: Repinotan 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Repinotan 0.5 mg/day
Study: 15825548
Drug: Repinotan 1.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Repinotan 1.25 mg/day
Study: 15825548
Drug: Repinotan 2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Repinotan 2.5 mg/day
Study: 12861157
Drug: Chlorhexidine vaginal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlorhexidine vaginal irrigation (200 mL of 0.2% chlorhexidine solution every 6 hours during labor)
Study: 12861157
Drug: Placebo (sterile
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (sterile saline solution every 6 hours during labor)
Study: 10868308
Drug: Midazolam syrup
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Midazolam syrup (0.25, 0.5, or 1.0 mg/kg)
Study: 10868308
Drug: Midazolam syrup
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Midazolam syrup (0.25 to 1.0 mg/kg)
Study: 10868308
Drug: Midazolam syrup
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Midazolam syrup (1.0 mg/kg)
Study: 27875025
Drug: Hyperinsufflation (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyperinsufflation (15 minutes, twice daily)
Study: 18155811
Drug: Combined intradermal
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined intradermal (ID) BCG and Hepatitis B (HbsAg 10 microg plus BCG suspension 0.1mg)
Study: 18155811
Drug: Intramuscular (IM)
Normalized name: intramuscular immunoglobulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular (IM) Hepatitis B
Study: 10817849
Drug: Nitrate+ (patients
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitrate+ (patients using nitrate-containing drugs)
Study: 10817849
Drug: Nitrate- (patients
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitrate- (patients not using nitrate-containing drugs)
Study: 8911839
Drug: Low-dose fentanyl
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose fentanyl anaesthesia + thoracic epidural analgesia
Study: 949108
Drug: High-dose fentanyl
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose fentanyl anaesthesia
Study: 1687200
Drug: Ismo-Retard 40
Normalized name: isosorbide mononitrate Extended Release Oral Tablet [Ismo Retard]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ismo-Retard 40 mg
Study: 1687200
Drug: Ismo-Retard 40
Normalized name: isosorbide mononitrate Extended Release Oral Tablet [Ismo Retard]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ismo-Retard 40 mg (15 consecutive once-daily doses)
Study: 1687200
Drug: Imdur 60
Normalized name: Imdur 60mg Extended-Release Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imdur 60 mg
Study: 1687200
Drug: Imdur 60
Normalized name: Imdur 60mg Extended-Release Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imdur 60 mg (15 consecutive once-daily doses)
Study: 6637313
Drug: Intravenous injection
Normalized name: Meta Trace FDG, intravenous injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous injection of indomethacin (Confortid) 50 mg
Study: 6637313
Drug: Subcutaneous injection
Normalized name: EPINEPHRINE 0.3 mg SUBCUTANEOUS INJECTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous injection of 2 mg hydromorphine chloride-atropine (Dilaudid-atropin 1 ml) with a suppository of prochlorperazine (Stemetil) 25 mg
Study: 30952748
Drug: Standard Temozolomide-based
Normalized name: Temozolomide
DrugBank: Temozolomide (DB00853)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Standard Temozolomide-based therapy
Study: 25069201
Drug: Warm acupuncture
Approvals — FDA: no, EMA: no, PMDA: no
Description: Warm acupuncture stimulation of TE 5 combined with routine acupuncture and rehabilitation training (30 min, once daily)
Study: 25069201
Drug: Routine acupuncture
Normalized name: Peace Out Acne Hero Routine KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine acupuncture stimulation of the same acupoints and rehabilitation training (30 min, once daily)
Study: 17289685
Drug: Three months
Normalized name: three-lobe sage extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three months of anticoagulation with heparin for five days followed by warfarin (n=369)
Study: 17289685
Drug: Six months
Approvals — FDA: no, EMA: no, PMDA: no
Description: Six months of anticoagulation with heparin for five days followed by warfarin (n=380)
Study: 11413078
Drug: Transdermal estradiol
Normalized name: estradiol Transdermal System
DrugBank: Estradiol (DB00783)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Transdermal estradiol (200 microgram/d)
Study: 9327783
Drug: Oral conjugated
Normalized name: Conjugated Estrogens
DrugBank: Conjugated estrogens (DB00286)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral conjugated estrogens (0.625 mg/d)
Study: 11413078
Drug: Intravenous conjugated
Normalized name: Conjugated Estrogens
DrugBank: Conjugated estrogens (DB00286)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous conjugated estrogens
Study: 11413078
Drug: Sublingual estradiol
Normalized name: Estradiol
DrugBank: Estradiol acetate (DB13952)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sublingual estradiol
Study: 9641731
Drug: Recombinant human
Normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Recombinant human growth hormone (r-hGH) treatment at a dosage of 0.2 IU/kg/body weight (0.067 mg/kg) subcutaneously daily for 3 years.
Study: 9641731
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (Group 2) with a 1-year observation period followed by a 3-year treatment period.
Study: 6781189
Drug: Heparin administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin administered at an early stage
Study: 6781189
Drug: Heparin administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin administered at a late stage
Study: 31124839
Drug: Manual bolus
Normalized name: Peumus boldus leaf extract
DrugBank: Boldo leaf extract (DB15815)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Manual bolus atomization of bupivacaine (1.25 mg/kg diluted in 30 mL normal saline over 30 seconds)
Study: 26357864
Drug: Clonidine (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clonidine (25 μg or 50 μg twice daily for 9 weeks)
Study: 21146661
Drug: Triple antiplatelet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple antiplatelet therapy (500 mg aspirin, 600 mg clopidogrel, and tirofiban 25 μg/kg bolus and 0.15 μg/kg per minute maintenance infusion for 18 hours)
Study: 16421011
Drug: Triple antiplatelet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple antiplatelet therapy
Study: 21146661
Drug: Dual antiplatelet
Normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dual antiplatelet therapy (500 mg aspirin and 600 mg clopidogrel)
Study: 15860853
Drug: 4‐OHT gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4‐OHT gel (0.5, 1, or 2 mg/d)
Study: 15860853
Drug: Oral tamoxifen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral tamoxifen (20 mg/d)
Study: 12475151
Drug: Fixed-dose combination
Normalized name: Progestogens and estrogens, fixed combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed-dose combination (FDC) of Rifater (RFT)/Rifinah (RFN)
Study: 12475151
Drug: Separate regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Separate regimen of four component drugs (INH, RMP, EMB, PZA)
Study: 10561143
Drug: Soft Gelatin
Normalized name: Norvir Soft Gelatin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Soft Gelatin Capsule (SGC) formulation
Study: 10561143
Drug: Oral solution
Normalized name: Oral Solution
DrugBank: Sodium citrate (DB09154)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral solution formulation
Study: 1071698
Drug: Active treatment
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active treatment (chlorothiazide + alpha-methyldopa and/or a beta-adrenoreceptor antagonist as required)
Study: 28012300
Drug: Internet-delivered cognitive
Normalized name: DELIVER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Internet-delivered cognitive behavior therapy (ICBT)
Study: 21957933
Drug: Guided self-help
Normalized name: loratadine
DrugBank: Loratadine (DB00455)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Guided self-help or e-mail therapy (original trial)
Study: 9159346
Drug: Ciprofloxacin prophylaxis
Normalized name: Ciprofloxacin
DrugBank: Ciprofloxacin (DB00537)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ciprofloxacin prophylaxis (500 mg orally twice a day)
Study: 2816477
Drug: Oral contraceptives
Normalized name: VCF Contraceptive
DrugBank: Nonoxynol-9 (DB06804)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral contraceptives for 30 days
Study: 2816477
Drug: Oral contraceptives
Normalized name: VCF Contraceptive
DrugBank: Nonoxynol-9 (DB06804)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral contraceptives for 15 days
Study: 808126
Drug: Keflex and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Keflex and Keflin (therapeutic doses)
Study: 28851933
Drug: 0.5 ml/kg/min
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 ml/kg/min ELO‐MEL‐isoton (osmolarity = 302 mosmol/l) for 60 minutes
Study: 22161694
Drug: Donepezil (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Donepezil (5 mg daily for 14-17 days)
Study: 16784965
Drug: Chromium-containing milk
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chromium-containing milk powder (200 microg/20 g milk powder) twice a day for 16 weeks
Study: 15572756
Drug: Beta-carotene (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beta-carotene (30 mg) and retinyl palmitate (25,000 IU)
Study: 11230889
Drug: Hyperbaric oxygen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyperbaric oxygen (HBO2) therapy, 100% oxygen for 100 min in a multiplace hyperbaric chamber on 30 occasions over a period of 6 weeks.
Study: 9425965
Drug: 4 mg
Normalized name: lutein 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 mg bupivacaine
Study: 9425965
Drug: 6 mg
Normalized name: boron 6 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 mg bupivacaine